Participants:18–64 years · 65+ years · Healthy volunteers
Substances:SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER

Contact Research Centre

Obesity

Not recruiting

InvestigationalNo placebo

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cagrilintide

Contact Research Centre

Cervix carcinoma+1

Not recruiting

Registered drugNo placebo

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Registered drugNo placebo

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Registered drugNo placebo

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Ovarian cancer

Not recruiting

Registered drugNo placebo

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tuvusertib

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Triple negative breast cancer

Not recruiting

Registered drugNo placebo

A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Domvanalimab

Contact Research Centre

COVID-19

Not recruiting

Registered drugNo placebo

A study to test the safety and immune response of PHH-1V111 vaccine against COVID-19 variants in adults

Registered drugNo placebo

Spain

Participants:65+ years · Healthy volunteers

Contact Research Centre

Find therapies in clinical trials near you – page 14

295 trials match your criteria

Bladder cancer

Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

Colitis ulcerative

Study on the Effectiveness and Safety of Guselkumab for Patients with Moderate to Severe Ulcerative Colitis

Ischaemic stroke+2

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

COVID-19

Safety and Immunogenicity of SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER Vaccine in Adults with COVID-19

Obesity

Weight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone

Cervix carcinoma+1

Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

Colorectal cancer metastatic

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Squamous cell carcinoma of head and neck

A study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery

Ovarian cancer

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Triple negative breast cancer

A study testing zimberelimab, domvanalimab, and sacituzumab govitecan for patients with PD-L1 positive advanced triple-negative breast cancer

COVID-19

A study to test the safety and immune response of PHH-1V111 vaccine against COVID-19 variants in adults

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.